P/B
1,3
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
$180.6M
Market Cap • 10/2/2026
2014
(12 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2
EPS
—
Market Cap
Market Cap
180,6M
EV
39,6M
EV/Revenue
0
EV/EBITDA
-0,3
EV/EBIT
-0,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
3,1%
Total Yield
3,1%
Payout
0%
Retained Earnings
-1,3B
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
12,7%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
-3,2%
CAGR Net Income 5Y
-5%
CAGR EPS 5Y
-15,8%
CAGR OCF 5Y
-0,5%
Leverage
N.D./EBITDA
0,9
Debt/Equity
0%
Current Ratio
4,8
Quick Ratio
4,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!